Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses

Toxicokinetics describes the concentration and time course of a xenobiotic in the circulation under the conditions of a toxicology study. However, the fundamental challenge to the toxicologist, of extrapolating the findings in animals to a risk assessment in humans, requires knowledge and understanding of both the pharmacokinetics and pharmacodynamic responses in each species. This paper exemplifies situations where measurement of plasma concentrations may provide information useful in the design and interpretation of the toxicity observed in a given species; it also illustrates how intrinsic interspecies differences in pharmacodynamic response limit the extrapolation of toxicity data across species. The special case of the multistage cumulative phenomenon of carcinogenicity, with the implications of daily dose, duration of dosing, and species differences in response, is also discussed.

[1]  K S Crump,et al.  Correlation between carcinogenic potency of chemicals in animals and humans. , 1988, Risk Analysis.

[2]  B. Ames,et al.  Too many rodent carcinogens: mitogenesis increases mutagenesis. , 1990, Science.

[3]  J. Palacios,et al.  α1-adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates , 1987, Brain Research.

[4]  R. Maronpot,et al.  Correlation of hepatocellular proliferation with hepatocarcinogenicity induced by the mutagenic noncarcinogen:carcinogen pair--2,6- and 2,4-diaminotoluene. , 1991, Toxicology and applied pharmacology.

[5]  Gavin Kilpatrick,et al.  Inter-species variants of the 5-HT3 receptor. , 1992, Biochemical Society transactions.

[6]  D. Lowenthal,et al.  Geriatric pharmacology: basic and clinical considerations. , 1992, Annual review of pharmacology and toxicology.

[7]  A. Monro The paradoxical lack of interspecies correlation between plasma concentrations and chemical carcinogenicity. , 1993, Regulatory toxicology and pharmacology : RTP.

[8]  A. Monro,et al.  What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.

[9]  R. Shepard,et al.  Pharmacokinetics of azithromycin in rats and dogs. , 1990, The Journal of antimicrobial chemotherapy.

[10]  D W Nebert,et al.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.

[11]  A. Monro How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? , 1993, Adverse drug reactions and toxicological reviews.

[12]  S H Moolgavkar,et al.  Mutation and cancer: a model for human carcinogenesis. , 1981, Journal of the National Cancer Institute.

[13]  G Goodman,et al.  Predicting the carcinogenicity of chemicals in humans from rodent bioassay data. , 1991, Environmental health perspectives.

[14]  C. Haanen,et al.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients , 2004, Cancer Chemotherapy and Pharmacology.

[15]  J. Hopkins Interpretation of negative epidemiological evidence for carcinogenicity: Edited by N.J. Wald & R. Doll. International Agency for Research on Cancer, Lyon, 1985. pp. vii + 232. £20.00. ISBN 0-19-723065-2 , 1987 .

[16]  J. Haseman,et al.  An examination of the association between maximum-tolerated dose and carcinogenicity in 326 long-term studies in rats and mice. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[17]  L. Bernstein,et al.  Interspecies extrapolation in carcinogenesis: prediction between rats and mice. , 1989, Environmental health perspectives.

[18]  J. Huff,et al.  Scientific concepts, value, and significance of chemical carcinogenesis studies. , 1991, Annual review of pharmacology and toxicology.

[19]  S. Ebara,et al.  Repair of mucosal damage induced by ethanol in the rat stomach. Effects of concentration, exposure period and prostaglandins. , 1988, Digestion.

[20]  H. Kao,et al.  Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.

[21]  K. Küpfmüller,et al.  Quantitative Analyse der Krebsentstehung , 1948 .

[22]  P. N. Lee,et al.  Cancer and ageing in mice and men. , 1975, British Journal of Cancer.

[23]  D. Smith,et al.  Design of toxicokinetic studies. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  J. Willerson,et al.  Differences in myocardial α- and β-adrenergic receptor numbers in different species , 1983 .

[25]  D. Langin,et al.  Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. , 1991, European journal of pharmacology.

[26]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[27]  W. E. Lindup Plasma protein binding of drugs: some basic and clinical aspects , 1987 .

[28]  J. Palacios,et al.  Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites , 1986, Brain Research.

[29]  G Goodman,et al.  Quantitative prediction of human cancer risk from rodent carcinogenic potencies: a closer look at the epidemiological evidence for some chemicals not definitively carcinogenic in humans. , 1991, Regulatory toxicology and pharmacology : RTP.

[30]  H J Clewell,et al.  Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. , 1988, Toxicology letters.

[31]  L. Ellwein,et al.  Genetic errors, cell proliferation, and carcinogenesis. , 1991, Cancer research.

[32]  M. J. Coon,et al.  Cytochrome P450: progress and predictions , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  L. Chauvelot‐Moachon,et al.  Effect of recombinant human interleukin-1 beta and tumor necrosis factor alpha on liver cytochrome P-450 and serum alpha-1-acid glycoprotein concentrations in the rat. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[34]  L. Birnbaum Pharmacokinetic basis of age-related changes in sensitivity to toxicants. , 1991, Annual review of pharmacology and toxicology.

[35]  B S Pasternack,et al.  Use of human data in quantitative risk assessment of carcinogens: impact on epidemiologic practice and the regulatory process. , 1992, Regulatory toxicology and pharmacology : RTP.

[36]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[37]  B. Ames,et al.  Chemical carcinogenesis: too many rodent carcinogens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Smith,et al.  Role of metabolism and pharmacokinetic studies in the discovery of new drugs--present and future perspectives. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  J. Tillement,et al.  Diseases and Drug Protein Binding , 1978, Clinical pharmacokinetics.